4 completed. 3 Phase 1, 1 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 3 | Completed 3 |
| Phase 2 | 1 | Completed 1 |
Follow SB-485232: new trials by email Literature Review of SB-485232 trials Research Report on SB-485232
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Phase I, Dose-Escalation Study to Assess the Safety and Biological Activity of Recombinant Human Interleukin-18 SB-485232, Rituximab - Lymphoma, Non-Hodgkin | Phase 1 | Completed | GlaxoSmithKline | 24 | 2007-07-31 | 2017-07-26 |
| Anti-Tumor Activity Of SB-485232 In Patients With Previously Untreated Metastatic Melanoma SB-485232 - Melanoma | Phase 2 | Completed | GlaxoSmithKline | 64 | 2004-11-15 | 2017-07-27 |
| Dose-Escalating Study Of SB-485232 Administered Intravenously Every 28 Days To Adults With Solid Tumors Or Lymphomas SB-485232 - Solid Tumor Cancer, Lymphoma | Phase 1 | Completed | GlaxoSmithKline | 12 | 2004-04-01 | 2008-10-13 |
| Dose-Escalation Study Of SB-485232 Administered As Daily Subcutaneous Injections In Adults With Solid Tumors SB-485232 - Solid Tumor Cancer | Phase 1 | Completed | GlaxoSmithKline | 25 | 2003-01-01 | 2008-10-16 |
Neoplasms (2) · Lymphoma (1) · Lymphoma, Non-Hodgkin (1) · Melanoma (1)
GlaxoSmithKline (4)
United States (4) · Australia (1)